Literature DB >> 17324767

Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?

Thomas A Aloia1, Thomas E Aloia, Jeffrey E Lee, Jean-Nicolas Vauthey, Eddie K Abdalla, Robert A Wolff, Gauri R Varadhachary, James L Abbruzzese, Christopher H Crane, Douglas B Evans, Peter W T Pisters.   

Abstract

BACKGROUND: Delayed recovery after pancreaticoduodenectomy (PD) is believed to preclude adjuvant therapy for approximately 30% of patients who undergo elective PD as initial treatment for pancreatic adenocarcinoma. This study reexamined the frequency of delayed recovery and assessed other factors associated with adjuvant therapy administration after PD at a high-volume center. STUDY
DESIGN: Preoperative and perioperative variables were reviewed in a consecutive series of 85 patients with pancreatic adenocarcinoma undergoing PD without preoperative chemotherapy or radiotherapy from 1990 to 2004.
RESULTS: Study groups included patients undergoing emergency PD (group 1, n=13); elective PD with good preoperative Eastern Cooperative Oncology Group (ECOG) performance status (PS) (group 2, ECOG PS: 0 to 1, n=63); and elective PD with marginal preoperative PS (group 3, ECOG PS: 2 to 3, n=9). Delayed recovery of PS precluded adjuvant therapy in 23% of patients in group 1, 6% of patients in group 2, and 44% of patients in group 3 (p=0.0001).
CONCLUSIONS: The impact of delayed recovery after PD on the delivery of adjuvant therapy depends on the urgency of surgery and the preoperative PS. For patients with good preoperative PS who undergo elective PD at a high-volume center, it is uncommon for delayed recovery to preclude delivery of adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324767     DOI: 10.1016/j.jamcollsurg.2006.12.011

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  36 in total

1.  Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.

Authors:  Olivier Turrini; Joshua A Waters; Thomas Schnelldorfer; Keith D Lillemoe; Constantin T Yiannoutsos; Michael B Farnell; Michael G Sarr; C Max Schmidt
Journal:  HPB (Oxford)       Date:  2010-09       Impact factor: 3.647

2.  Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.

Authors:  Matthew H G Katz; Huamin Wang; Aparna Balachandran; Priya Bhosale; Christopher H Crane; Xuemei Wang; Peter W T Pisters; Jeffrey E Lee; Jean-Nicolas Vauthey; Eddie K Abdalla; Robert Wolff; James Abbruzzese; Gauri Varadhachary; Xavier Chopin-Laly; Chusilp Charnsangavej; Jason B Fleming
Journal:  J Gastrointest Surg       Date:  2011-11-08       Impact factor: 3.452

3.  Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.

Authors:  Ching-Wei D Tzeng; Matthew H G Katz; Jason B Fleming; Jeffrey E Lee; Peter W T Pisters; Holly M Holmes; Gauri R Varadhachary; Robert A Wolff; James L Abbruzzese; Jean-Nicolas Vauthey; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2013-10-16       Impact factor: 3.452

4.  Current status of adjuvant therapy for pancreatic cancer.

Authors:  Matthew H G Katz; Jason B Fleming; Jeffrey E Lee; Peter W T Pisters
Journal:  Oncologist       Date:  2010-11-02

5.  The Landmark Series: Preoperative Therapy for Pancreatic Cancer.

Authors:  Sameer H Patel; Matthew H G Katz; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2021-05-28       Impact factor: 5.344

6.  Surgical outcomes of pancreaticoduodenectomy for periampullary tumors in elderly patients.

Authors:  Yo-Ichi Yamashita; Ken Shirabe; Eiji Tsujita; Kazuki Takeishi; Tetsuo Ikeda; Tomoharu Yoshizumi; Yoshinari Furukawa; Teruyoshi Ishida; Yoshihiko Maehara
Journal:  Langenbecks Arch Surg       Date:  2013-02-15       Impact factor: 3.445

7.  Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy.

Authors:  Thomas A Aloia; Giuseppe Zimmitti; Claudius Conrad; Vijaya Gottumukalla; Scott Kopetz; Jean-Nicolas Vauthey
Journal:  J Surg Oncol       Date:  2014-05-21       Impact factor: 3.454

Review 8.  Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.

Authors:  Jeffrey M Sutton; Daniel E Abbott
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

9.  Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.

Authors:  Matthew H G Katz; Gauri R Varadhachary; Jason B Fleming; Robert A Wolff; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Charlotte C Sun; Huamin Wang; Christopher H Crane; Jeffrey H Lee; Eric P Tamm; James L Abbruzzese; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2010-02-17       Impact factor: 5.344

10.  Completion of adjuvant therapy in patients with resected pancreatic cancer.

Authors:  Danielle K DePeralta; Takuya Ogami; Jun-Min Zhou; Michael J Schell; Benjamin D Powers; Pamela J Hodul; Mokenge P Malafa; Jason B Fleming
Journal:  HPB (Oxford)       Date:  2019-09-25       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.